metformin has been researched along with Puberty, Precocious in 15 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Puberty, Precocious: Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin." | 9.15 | Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011) |
| "To study the effects of early metformin treatment on menarche, height, and polycystic ovary syndrome (PCOS) markers." | 5.15 | Early metformin therapy to delay menarche and augment height in girls with precocious pubarche. ( de Zegher, F; Diaz, M; Ibáñez, L; Lopez-Bermejo, A; Marcos, MV, 2011) |
| "In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin." | 5.15 | Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011) |
| "We studied the effects of the SHBG (TAAAA)(n) and androgen receptor gene [AR] (CAG)(n) allele length on endocrine-metabolic features and body composition (by dual-energy X-ray absorptiometry) before and after 1 year on metformin (850 mg/d) in 70 girls with polycystic ovary syndrome after precocious pubarche; allele lengths were assessed by polymerase chain reaction in both patients and in population control subjects (n = 107)." | 5.14 | Efficacy of metformin therapy in adolescent girls with androgen excess: relation to sex hormone-binding globulin and androgen receptor polymorphisms. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Petry, CJ, 2010) |
| "Metformin-treated girls gained more height per bone-age year and had less visceral and hepatic fat." | 2.87 | Metformin for Rapidly Maturing Girls with Central Adiposity: Less Liver Fat and Slower Bone Maturation. ( de Zegher, F; García Beltrán, C; Ibáñez, L; López-Bermejo, A, 2018) |
| "Metformin-treated girls gained on average 5." | 2.73 | Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2008) |
| "Metformin treatment was associated with a less adipose body composition (and lower serum leptin levels) and with a 0." | 2.72 | Metformin treatment to prevent early puberty in girls with precocious pubarche. ( de Zegher, F; Dunger, DB; Ibáñez, L; Marcos, MV; Ong, K; Valls, C, 2006) |
| "In metformin-treated girls, all these abnormalities significantly reversed within 6 months, and body composition continued to improve between 6 and 12 months." | 2.71 | Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2004) |
| "Metformin treatment was well tolerated and was accompanied by a marked drop in hirsutism score, insulin response to oral glucose tolerance test, free androgen index, and baseline testosterone, androstenedione, dehydroepiandrosterone, and dehydroepiandrosterone sulfate levels (all P < 0." | 2.69 | Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. ( de Zegher, F; Ibáñez, L; Marcos, MV; Potau, N; Valls, C, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, Z | 1 |
| Sui, X | 1 |
| Li, L | 1 |
| Wang, Y | 1 |
| Zhao, J | 1 |
| de Zegher, F | 11 |
| García Beltrán, C | 1 |
| López-Bermejo, A | 6 |
| Ibáñez, L | 13 |
| Diaz, M | 6 |
| Marcos, MV | 7 |
| Petry, CJ | 1 |
| Brufani, C | 1 |
| Fintini, D | 1 |
| Nobili, V | 1 |
| Patera, PI | 1 |
| Cappa, M | 1 |
| Brufani, M | 1 |
| Lázaro, I | 1 |
| Cabré, A | 1 |
| Masana, L | 1 |
| Ferrer, A | 1 |
| Ong, K | 4 |
| Amin, R | 1 |
| Dunger, D | 1 |
| Valls, C | 3 |
| Dunger, DB | 3 |
| Zegher, Fd | 1 |
| Potau, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
1 review available for metformin and Puberty, Precocious
| Article | Year |
|---|---|
Use of metformin in pediatric age.
Topics: Adolescent; Antipsychotic Agents; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty | 2011 |
11 trials available for metformin and Puberty, Precocious
| Article | Year |
|---|---|
Metformin for Rapidly Maturing Girls with Central Adiposity: Less Liver Fat and Slower Bone Maturation.
Topics: Adiposity; Fatty Liver; Female; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Life Style; Metfor | 2018 |
Pubertal metformin therapy to reduce total, visceral, and hepatic adiposity.
Topics: Adiposity; Adolescent; Body Weight; Child; Comorbidity; Female; Follow-Up Studies; Humans; Hyperinsu | 2010 |
Efficacy of metformin therapy in adolescent girls with androgen excess: relation to sex hormone-binding globulin and androgen receptor polymorphisms.
Topics: Adolescent; Androgens; Biomarkers, Pharmacological; Child; Female; Humans; Hyperandrogenism; Hypogly | 2010 |
Early metformin therapy to delay menarche and augment height in girls with precocious pubarche.
Topics: Body Height; Child; Female; Humans; Hypoglycemic Agents; Infant, Low Birth Weight; Infant, Newborn; | 2011 |
Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.
Topics: Adolescent; Androgen Antagonists; Biomarkers; Body Mass Index; Child; Contraceptives, Oral, Combined | 2011 |
Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.
Topics: Adolescent; Child; Female; Follow-Up Studies; Hirsutism; Humans; Hyperandrogenism; Hypoglycemic Agen | 2011 |
Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome.
Topics: Adolescent; Body Composition; Body Constitution; Body Mass Index; Child; Disease Progression; Female | 2004 |
Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment.
Topics: Adiponectin; Body Composition; Child; Female; Humans; Hypoglycemic Agents; Insulin; Intercellular Si | 2004 |
Metformin treatment to prevent early puberty in girls with precocious pubarche.
Topics: Adrenarche; Body Composition; Body Mass Index; Child; Female; Humans; Hypoglycemic Agents; Infant, L | 2006 |
Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche.
Topics: Child; Female; Humans; Hypoglycemic Agents; Infant, Low Birth Weight; Infant, Newborn; Insulin-Like | 2008 |
Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
Topics: Adolescent; Adult; Blood Glucose; Female; Hirsutism; Hormones; Humans; Hyperandrogenism; Hyperinsuli | 2000 |
3 other studies available for metformin and Puberty, Precocious
| Article | Year |
|---|---|
The effect of metformin on low birth weight girls with precocious puberty: A protocol for systematic review and meta-analysis.
Topics: Female; Humans; Hypoglycemic Agents; Infant, Low Birth Weight; Infant, Newborn; Meta-Analysis as Top | 2022 |
Effects of growth hormone treatment on neutrophil count in children born small for gestational age.
Topics: Child; Growth Disorders; Human Growth Hormone; Humans; Hypoglycemic Agents; Infant, Newborn; Infant, | 2006 |
Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome.
Topics: Aging; Androgen Antagonists; Body Weight; Child; Drug Therapy, Combination; Female; Fetal Developmen | 2006 |